Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers

These studies were conducted to assess the systemic bioavailability of mometasone furoate (MF) administered by both the dry-powder inhaler (DPI) and the metered-dose inhaler with an alternate propellant (MDI-AP). The pharmacokinetics of single doses (400 micrograms) of MF administered by intravenous (i.v.) and inhalation routes was assessed in a randomized, three-way crossover study involving 24 healthy volunteers. In a separate study, 6 healthy subjects were administered a single dose of tritiated (3H-) MF by DPI, and the radioactivity in blood, urine, feces, and expired air was determined. Following i.v. administration, MF was detected in all subjects for at least 8 hours postdose. The half-life (t1/2) following i.v. administration was 4.5 hours. In contrast, following DPI administration, plasma MF concentrations were below the limit of quantification (LOQ, 50 pg/mL) for many subjects (10 of 24), and the systemic bioavailability by this route was estimated to be less than 1%. Only two plasma samples following MDI-AP administration had plasma concentrations of MF above the LOQ indicating no detectable systemic bioavailability in 92% of the subjects. A separate study with 6 healthy male subjects administered a single dose of 3H-MF (200 microCi) by DPI revealed that much of the dose (approximately 41%) was excreted unchanged in the feces (0-72 hours), while that which was absorbed was extensively metabolized. These results indicate that inhaled MF has negligible systemic bioavailability and is extensively metabolized and should therefore be well tolerated in the chronic treatment of asthma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. C. Hughes, P. C. Shardlow, F. J. Hollis, R. J. Scott, D. S. Motivaras, A. Allen, and V. M. Rousell Metabolism and Disposition of Fluticasone Furoate, an Enhanced-Affinity Glucocorticoid, in Humans Drug Metab. Dispos., November 1, 2008; 36(11): 2337 - 2344. [Abstract] [Full Text] [PDF]

				H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF]

				C. Leach, P. LeSouef, G. P. Chrousos, L. Ghaly, D. Iezzoni, A. Shedden, and A. G. Harris Mometasone and Beclomethasone Comparison Article Observations Chest, May 1, 2006; 129(5): 1389 - 1391. [Full Text] [PDF]

				S. Sahasranaman, M. Issar, and G. Hochhaus METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES Drug Metab. Dispos., February 1, 2006; 34(2): 225 - 233. [Abstract] [Full Text] [PDF]

				G. P. Chrousos, L. Ghaly, A. Shedden, D. G. Iezzoni, and A. G. Harris Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects Chest, July 1, 2005; 128(1): 70 - 77. [Abstract] [Full Text] [PDF]

				G. Hochhaus New Developments in Corticosteroids Proceedings of the ATS, November 1, 2004; 1(3): 269 - 274. [Abstract] [Full Text] [PDF]

				T. C. Fardon, D. K. C. Lee, K. Haggart, L. C. McFarlane, and B. J. Lipworth Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate Am. J. Respir. Crit. Care Med., November 1, 2004; 170(9): 960 - 966. [Abstract] [Full Text] [PDF]

				B. J. Lipworth and M. B. Affrime Mometason Furoate Levels Chest, September 1, 2001; 120(3): 1034 - 1035. [Full Text] [PDF]

				L-G. Carlsson and S. Edsbacker Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Eur. Respir. J., June 1, 2001; 17(6): 1332 - 1333. [Full Text] [PDF]